Previous Article | Next Article ![]()
Journal of Bacteriology, May 2006, p. 3299-3307, Vol. 188, No. 9
0021-9193/06/$08.00+0 doi:10.1128/JB.188.9.3299-3307.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Biology Department, University of Utah, Salt Lake City, Utah 84112
Received 21 May 2005/ Accepted 16 February 2006
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Chemoeffectors, sensed by the chemoreceptors, modulate CheA activity over a wide range. Unliganded receptors activate CheA several hundredfold over its basal, receptor-uncoupled autophosphorylation rate, whereas attractant-bound receptors deactivate CheA to about its basal activity level (8, 9, 26, 33, 45). CheA autophosphorylation control occurs in ternary complexes formed between the cytoplasmic signaling domains of the chemoreceptors, CheA, and the coupling protein CheW, which is essential for chemotactic behavior in vivo and for receptor-mediated activation of CheA in vitro. The role of CheW in receptor coupling control of CheA is poorly understood, owing to a paucity of structural information about the receptor signaling complex. However, in vitro CheW binds both to receptors (10, 17, 25, 29, 42) and to CheA (10, 16, 31, 38), so it may serve to couple ligand-induced conformational changes in the receptor to corresponding structural changes in CheA that allosterically regulate its activity. A better understanding of the CheA-CheW binding interaction could provide useful insights into the mechanism of receptor-mediated control of CheA.
The CheA protein of E. coli functions as a homodimer; the 654-residue subunits have a modular architecture consisting of five functional domains (Fig. 1A). Autophosphorylation involves interaction of the N-terminal phosphorylation site domain (P1) in one subunit with the ATP-binding domain (P4) of the other subunit (46, 47, 51). The principal dimerization determinants lie in the central P3 domain (5, 23). The C-terminal P5 domain is not required for autophosphorylation but is essential for coupling CheA activity to chemoreceptor control (12) and contains determinants for a CheA-CheW binding interaction (11, 38). CheA molecules lacking part or all of the P5 domain cannot undergo activation by chemoreceptors (12) and fail to bind to CheW molecules bearing an N-terminal fluorescein (11) or glutathione S-transferase (GST) affinity handle (38). Thus, the P5 domain is most likely the binding target for CheW, but the CheW-binding determinants and the location of the binding surface on the P5 domain have not been established.
|
| MATERIALS AND METHODS |
|---|
|
|
|---|
cheA1643) (39), RP3098 [
(flhD-flhB)4] (44), RP9540 [
cheA1643
tsr-7028
(tar-tap)5021
trg-1] (28), RP9542 (
cheA1643
cheZ6725) (28), and RP9543 [
cheA1643
tsr-7028
(tar-tap)5021
trg-1
cheZ6725] (32). Strain RP526 carries the mutD5 mutator allele (14). Plasmid pKJ9 confers ampicillin resistance and expresses functional CheA inducible by isopropyl-ß-D-thiogalactopyranoside (IPTG) (15, 21). This high-copy plasmid was used for purification of CheA proteins for in vitro studies. Plasmid pPA113, obtained from Peter Ames (University of Utah), confers chloramphenicol resistance and expresses functional CheA inducible by sodium salicylate. It was constructed by inserting the PCR-amplified cheA gene between the NdeI and KpnI restriction sites of expression vector pLC112 (2). This plasmid was used for in vivo assays of CheA function.
Plasmid pCJ30 is an IPTG-inducible expression vector derived from pBR322 (4, 6); pJC3 is a derivative of pCJ30 that carries wild-type tsr (13); pAR1.CheY, kindly provided by Rick Stewart (University of Maryland), expresses cheY from an IPTG-inducible promoter; pPA770, obtained from Peter Ames (University of Utah), expresses cheW from an IPTG-inducible promoter; and pPA117 was generated by inserting cheW into pGEX-3X, a GST gene fusion vector obtained from Amersham Biosciences.
Growth media. Chemotactic ability was assessed on semisolid tryptone medium (tryptone soft agar), consisting of tryptone broth (10 g tryptone, 5 g NaCl per liter) and 0.27% agar. L broth (tryptone broth plus 0.5% yeast extract) was generally used for growth of bacterial strains. H1 minimal salts medium (35) contained 1% Casamino Acids, 0.4% glycerol, and required amino acids (1 mM each) and was used as the growth medium for protein purification and protein stability assays. IPTG and sodium salicylate were purchased from Promega Corp. Ampicillin and chloramphenicol were purchased from Sigma Chemical Co. and used at 100 µg/ml and 25 µg/ml, respectively, in solid and liquid media, except in soft-agar chemotaxis assay plates, where their concentrations were halved.
CheA P5 mutant hunt. Plasmids pKJ9 and pPA113 were subjected to random mutagenesis by propagation in RP526, a proofreading-deficient polymerase mutant (14). To identify RP526 clones that retained high mutator activity, single colonies were grown overnight in L broth at 37°C and approximately 108 cells were spread on L plates containing 30 µg/ml nalidixic acid. Cultures that exhibited high frequencies (at least 105) of nalidixic acid-resistant mutants were used as plasmid hosts.
Independent plasmid pools from RP526 were transferred to strain RP9535 by CaCl2 transformation. Samples of the transformation reaction mixture were added to an empty petri dish, mixed with 25 ml of tryptone broth containing 0.2% agar and selective antibiotic. These maxiswarm plates were allowed to stand at room temperature for 1 to 2 h to gel and then incubated at 35°C. After overnight growth, the plates were screened for small, nonchemotactic colonies embedded in a diffuse background of chemotactic cells that had spread throughout the plates. (The inoculum size was adjusted to yield about 5,000 to 10,000 transformant colonies per plate.) Candidate mutants were single colony purified and retested for chemotaxis defects on tryptone soft agar at 32.5°C for 8 h.
Crude mapping tests with
fla transducing phages (36) were used to identify mutant plasmids with mutations in the P5 coding segment of cheA. RP9535 cells carrying candidate plasmids were picked to tryptone soft agar plates containing
109 particles of
fla2 or
fla3
30 (Fig. 1) and scored for formation of chemotactic recombinants after incubation at 32.5°C for 8 h. Mutant plasmids that recombined with
fla3
30 but not
fla2 were kept for DNA sequencing, performed at the Protein-DNA Core Facility at the University of Utah.
Pseudotaxis assays for CheA function. Mutant pPA113 plasmids were introduced by transformation into RP9540, RP9543, and RP9542, with selection on L plates containing 25 µg/ml chloramphenicol. After overnight incubation at 37°C, single colonies were picked to tryptone soft agar plates containing various concentrations of sodium salicylate and 12.5 µg/ml chloramphenicol. Colony sizes were compared after incubation for 12 to 17 h at 32.5°C.
CheA in vivo stability test. Strain RP9535 carrying the mutant pKJ9 or pPA113 plasmid was grown to mid-log phase (optical density at 600 nm of 0.5) in H1 medium at 35°C. CheA expression was induced by addition of 1 mM IPTG (pKJ9) or 20 µM sodium salicylate (pPA113), and the cells were grown for an additional 2 hours at 35°C. Cells were then collected by centrifugation, washed once with 5 volumes of H1 medium containing no amino acid supplements or other carbon and energy sources, and resuspended in an equal volume of the same medium. For cells carrying pKJ9 plasmids, 100 µg/ml chloramphenicol was also added to further prevent protein synthesis. The cells were incubated at 35°C with shaking, and 1-ml samples were collected at various time points, flash frozen, and stored at 70°C until all samples had been collected. Cells were then broken by three cycles of freezing and boiling in sodium dodecyl sulfate (SDS) sample buffer (24). The cell extracts were subjected to 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and the amount of full-length CheA protein at each time point was determined by quantitative Western blotting using a polyclonal anti-CheA rabbit antiserum, provided by Phil Matsumura (University of IllinoisChicago).
Purification of mutant CheA proteins.
Wild-type and all mutant CheA proteins were expressed from plasmid pKJ9 in strain RP3098 and purified by previously described methods (20). Briefly, cells were grown to mid-log phase (optical density at 600 nm of
0.5) in H1 medium at 35°C. CheA expression was induced with 1 mM IPTG, and the cells were grown for an additional 4 hours at 35°C. Cells were harvested by centrifugation, washed three times in 25 mM Tris (pH 7.5) plus 5 mM EDTA, and resuspended in TEDG-10 buffer (50 mM Tris-HCl [pH 7.5], 2 mM dithiothreitol, 0.5 mM EDTA, and 10% glycerol). After two cycles of disruption in a French press, cellular debris was removed by centrifugation for 25 min at 10,000 x g and the membranes were removed by centrifugation for 1 hour at 100,000 x g. The CheA protein in the clarified lysate was concentrated by a 25 to 40% ammonium sulfate precipitation and then purified on a 25-ml DEAE (DEAE cellulose) ion-exchange column with elution at
200 mM NaCl. The column fractions were collected and concentrated by ammonium sulfate precipitation and applied to a 400-ml S300 gel filtration column. CheA-containing fractions were concentrated again, dialyzed twice against 2 liters of TEDG-10 buffer for 12 h at 4°C, and stored at 70°C. Phenylmethylsulfonyl fluoride (1 mM) was used as a protease inhibitor throughout the purification process.
In vitro assays of mutant CheA proteins. CheA autophosphorylation was assessed at a 1-µM concentration in phosphorylation buffer (50 mM Tris-HCl [pH 7.5], 50 mM KCl, 5 mM MgCl2) at room temperature as previously described (1). CheA activation in ternary signaling complexes was assessed with reaction mixtures containing purified CheW and CheY proteins, prepared as described previously (1, 30), and membranes containing the serine receptor Tsr, prepared as described previously (7). Coupling reaction mixtures contained 0.5 µM CheA, 2 µM CheW, 25 µM CheY, and 4 µM Tsr in membrane, and reactions were carried out as described previously (32). CheA deactivation was measured in the same manner as activation except that the reaction mixtures also contained 1 mM serine.
CheA-CheW binding assays. GST-CheW and GST proteins were, respectively, expressed from pPA117 and pGEX-3X in strain RP3098 and purified according to the standard protocol provided by Amersham Biosciences. For CheA-CheW pull-down assays, glutathione-Sepharose beads were washed three times by being mixed with 10 volumes of phosphorylation buffer and pelleted in a table-top centrifuge. Washed beads (50 µl) were mixed with 50 µl of phosphorylation buffer containing either 430 µg GST-CheW or 250 µg GST and incubated at 4°C for at least 2 hours. Just before use, beads were washed three times with 10 volumes of wash buffer to remove unbound GST proteins. Washed beads were mixed with an equal volume of wash buffer, and the bead suspension was distributed to small centrifuge tubes in 10-µl aliquots. CheA samples (30 µl for each binding test) were adjusted to 50 µM with phosphorylation buffer, incubated at room temperature for 30 min, and then mixed with the beads and incubated at room temperature for 1 hour. Bead-plus-CheA mixtures were pelleted and then washed two to three times with 60 volumes of wash buffer. After removal of the final supernatant, beads were mixed with 30 µl of SDS sample buffer and boiled for 5 minutes. Samples were analyzed by SDS-PAGE, and proteins were detected by Coomassie staining or immunoblotting for quantification.
| RESULTS |
|---|
|
|
|---|
cheA tester strain (RP9535), and screened for chemotaxis defects by a variation of the miniswarm plate method (35). Altogether, 200 independent plasmid pools (50 for pKJ9 and 150 for pPA113) were screened for nonchemotactic mutants, which occurred at a frequency of about 103 after mutD mutagenesis. To identify possible P5 mutations, about 8 to 10 mutant isolates from each pool were subjected to mapping tests with two
fla transducing phages that carry different portions of the cheA coding region (Fig. 1A). We looked for plasmids that produced che+ recombinants with
fla3
30, which carries the entire P5 coding region and the C-terminal portion of the P4 coding region (36, 43). At most, one such plasmid was kept for DNA sequence analysis from each pool to ensure that all mutations had independent origins. The P5 mutant hunt yielded a total of 95 independent isolates. Of these, eight carried P5 nonsense mutations, three carried double mutations, and nine had mutations in the P4 coding region. The remaining 75 isolates carried P5 missense (P5*) mutations representing 16 amino acid replacements at 14 different residues (Table 1, mutant groups 1 to 3). Because each mutant amino acid change was found independently at least three times and on average nearly six times, we conclude that the P5 mutant hunt is saturated for the chemotaxis-defective phenotypes we sought.
|
Chemotactic ability of CheA P5 mutants.
Mutant pPA113 plasmids were used to express CheA P5 missense proteins in strain RP9535 (
cheA). Chemotactic ability of the strains was evaluated by colony morphology in tryptone soft agar containing 0.4 µM sodium salicylate, the inducer concentration that produced optimal complementation by wild-type pPA113. Representative mutant phenotypes are shown in Fig. 1B. All P5* mutants except the V606M, G627D, and G627S mutants were, as expected, significantly defective in supporting chemotaxis (Table 1). The nature of those chemotaxis defects was investigated with additional in vivo and in vitro functional tests.
In vivo autophosphorylation activity of P5* mutants. Two tests were used to evaluate the in vivo autophosphorylation ability of the mutant CheA proteins. Both tests exploited the phenomenon of pseudotaxis, which measures the ability of nonchemotactic cells to maneuver through soft agar by virtue of their unmodulated pattern of flagellar rotation. Cells that incessantly tumble (CW rotation) or that move only in forward runs (counterclockwise [CCW] rotation) spread more slowly than do cells that alternate running and tumbling episodes (3, 50). In the first test, mutant pPA113 plasmids were transferred into strain RP9540, which is deleted for the chromosomal cheA and four MCP chemoreceptor genes (Fig. 2). Although the aerotaxis transducer Aer is still present in RP9540, Aer alone does not detectably activate CheA, owing to its low abundance (27). Nevertheless, receptor-uncoupled CheA molecules that are able to autophosphorylate can contribute to phospho-CheY production in RP9540. At a sufficiently high expression level, basal CheA autophosphorylation activity generates enough phospho-CheY to cause a significant CW shift in flagellar rotation pattern, resulting in enhanced pseudotactic spreading (e.g., wild-type and A622V proteins [Fig. 2]). In contrast, autophosphorylation-deficient CheA proteins cause slow colony expansion at all expression levels (e.g., vector control and L559P and L552R proteins [Fig. 2]). The RP9540 test allowed us to make a provisional classification of the P5* mutants as either competent or incompetent for autophosphorylation.
|
|
|
In vivo stability of mutant CheA proteins. Because our mutant hunt emphasized loss-of-function phenotypes, some of the P5* proteins might be grossly misfolded or otherwise unstable in vivo. To identify unstable proteins, we tested their intracellular degradation rates after blocking protein synthesis in log-phase cultures, as detailed in Materials and Methods. We found that under these conditions wild-type CheA is degraded slowly, with over 70% of the initial molecules still present at 4 hours (Fig. 5). The mutant proteins in groups 2 to 4 (Table 1) had wild-type stabilities, but all group 1 proteins were rapidly degraded, declining to 30% or less of their initial levels (Fig. 5). The mutant residues in the group 1 proteins appear to be located predominantly at buried positions in the P5 structure (see Discussion), consistent with the possibility that these mutant proteins are misfolded.
|
|
Receptor-mediated activation and deactivation. P5* proteins were mixed with CheW and Tsr-containing membranes to evaluate their coupling control in ternary signaling complexes. Group 2 mutant proteins (K616E, A622V, G629D, and V631M), which exhibited activation defects in vivo, were also activation defective in vitro (Table 2). Whereas wild-type CheA was activated nearly 200-fold, the mutant proteins were activated at most a fewfold. In contrast, the group 3 and group 4 mutant proteins were activated 120-fold or more, consistent with their in vivo behavior. Receptor-mediated activation is reversed in the presence of attractant ligands. When tested for deactivation by serine-occupied Tsr, the group 3 mutant proteins (R555Q, I581V, and G588S) responded in the same manner as wild-type CheA, with autophosphorylation activities just a fewfold above the basal rates (Table 2). However, the group 4 mutant proteins (V606M and G627S) showed significantly less deactivation, with autophosphorylation rates more than 25-fold higher than uncoupled CheA activity (Table 2). The structural lesions in these proteins may specifically interfere with conformational changes that accompany ligand-induced down-regulation of CheA by receptor signaling complexes.
CheW binding. P5* proteins were tested for CheW binding with a GST-CheW pull-down assay. Previous binding studies using surface plasmon resonance showed that this GST-CheW derivative bound to CheA with the same affinity as wild-type CheW and that binding was dependent on the P5 domain of CheA (38). In the pull-down assay, group 2 mutant proteins exhibited binding signals below 20% that of the wild type (Table 2). Thus, their inability to undergo receptor-mediated activation could be due to a CheW-binding defect that prevents ternary-complex formation. The group 3 and group 4 mutant proteins showed slightly reduced but nevertheless substantial binding in this assay (at least 40% of the wild-type signal). These minor deficits in CheW binding may be functionally insignificant because both groups of P5* proteins showed robust levels of receptor activation, implying normal ternary-complex formation. In this regard, the I581V protein is especially noteworthy because all of its in vitro activities, including CheW binding, are very close to those of the wild-type protein. In vivo, the I581V protein is stable and hence apparently properly folded, yet it cannot support normal chemotactic behavior. We conclude that the I581V protein is defective in a signaling function for which there is no in vitro assay at present.
| DISCUSSION |
|---|
|
|
|---|
0.2-Å root mean square deviation for backbone atoms), and we used the E. coli coordinates to compare the structural and functional features of the CheA P5 mutants. Previously proposed CheW-binding regions in P5. Two folding subdomains related by pseudo-twofold symmetry comprise the CheA P5 domain (5, 18, 19) (Fig. 6B). Both resemble the SH3 domain of human c-Src kinase, a structural motif that promotes protein-protein interactions in various contexts (22, 52). Interestingly, P5's binding partner, CheW, is also an SH3-like protein, closely related both evolutionarily and structurally to P5 (5, 18, 19). Two hydrophobic surface patches in subdomain 2 have been suggested, on the basis of rather indirect evidence, to be the binding surface for CheW (5, 41) (Fig. 6A). Neither of these two proposed CheW-binding pockets is consistent with our missense mutation study, as explained below.
|
(i) Group 1. Group 1 lesions (Fig. 6A and B) destabilized P5, presumably through defects in folding or native structure. Although subject to rapid in vivo degradation, the mutant proteins had detectable autophosphorylation activity, implying that the misfolded P5 domains did not interfere with the functions of neighboring domains. These mutations most likely impair chemotaxis by drastically lowering steady-state CheA levels and, possibly, by disrupting normal receptor-coupling controls as well. Four of the seven sites identified by group 1 mutations are buried hydrophobic residues, three in subdomain 2 (L552, L559, and I584) and one (L526) in subdomain 1 at its interface with subdomain 2 (Fig. 6A). In all cases, the mutated amino acids have polar character and would be expected to disrupt core hydrophobic packing interactions. Two other hydrophobic group 1 residues (L542 and L545) are only partially buried and reside in the hydrophobic surface patch at the P3-distal end of P5 subdomain 2 (Fig. 6A). The final group 1 residue (Q641) also lies near the subdomain 1-subdomain 2 interface but at the C terminus of P5. This is the last residue of the T. maritima protein, but the E. coli protein has 14 more residues beyond this position, which might contribute additional stabilizing interactions for subdomain 2.
(ii) Group 3. Group 3 mutations impaired the in vivo chemotactic function(s) of CheA, but the mutant proteins exhibited no significant in vitro defects. The group 3 mutations occurred at three residues in subdomain 2 (Fig. 6A and B). Although these mutant proteins cannot fully support chemotaxis, the nature of their functional defect is unclear and may not be related to their CheW-binding ability, which was ostensibly normal in the in vitro GST-CheW pull-down assay.
(iii) Group 4. Group 4 CheA lesions did not impair chemotactic ability and were instead isolated as cheA mutations that could phenotypically suppress receptor mutants with CCW-biased signal states (28). The mutant proteins assembled activated ternary complexes in vitro that were not fully deactivated by attractant stimuli. Attenuated deactivation could account for their in vivo suppression effects, as this should enhance steady-state CheA activity and thereby offset the reduced activation ability of CCW-biased receptors. The group 4 residues (V606 and G627) are located in P5 subdomain 1, at the interface with P3/P3' (Fig. 6).
(iv) Group 2. Group 2 mutations caused substantial defects in CheW binding and receptor-mediated CheA activation. Although we did not directly assess ternary-complex formation in the present study, it seems likely that the activation defect of these mutant proteins reflects a failure to assemble ternary complexes, presumably due to their CheW-binding defect. The four group 2 residues are located in subdomain 1, near the interface with P3/P3' (Fig. 6). Three (K616, G629, and V631) are surface exposed on the same face of P5 (Fig. 6C); the other (A622) is partly buried on an opposing face of P5 (Fig. 6C).
Location of the P5-dependent CheW-binding site. The group 2 mutations, the only P5 lesions that affected CheW binding in vitro, must define important binding determinants. The most parsimonious interpretation is that group 2 mutations affect residues directly involved in the binding interaction, which implies that CheW binds primarily to P5 subdomain 1. Although much of the subdomain 1 surface seems to be inaccessible to CheW in the P3-P4-P5 crystal structure, CheA could conceivably undergo domain rearrangements in solution that expose the site proposed for CheW binding. In fact, the structure of a Thermotoga P4-P5/CheW complex, recently determined by Park et al. (34), is fully consistent with the proposed CheW interaction surface delineated by the group 2 P5 mutations in E. coli CheA.
Domain movements involved in CheA control. The group 4 mutations, which are defective specifically in CheA deactivation, suggest that P5 domain movements also play an important role in receptor-mediated control. The group 4 residues (V606 and G627) reside directly at the P5-P3 interface (Fig. 6), where even subtle conformational changes might alter the spatial relationship between the two domains. The group 4 mutations introduce amino acids with larger side chains, which might also retard dynamic relative motions of the two domains.
In summary, we propose that CheW binds to subdomain 1 of the CheA P5 domain. Dynamic motion of the P5 domain relative to other parts of CheA may control CheW access as well as subsequent conformational changes in the ternary signaling complex that modulate CheA activity. The group 4 P5 lesions, which allow CheW binding and ternary-complex formation, specifically interfere with CheA deactivation, most likely by blocking movements of the P5 domain relative to the P4 and P3 domains. Although this model accounts for the in vitro defects of group 2 and group 4 P5 mutants, it cannot explain the in vivo defects of group 3 mutants, which have no apparent functional defects in vitro. These mutants indicate that additional or alternative P5 interactions, not currently measurable in vitro, are important for CheA signaling in vivo.
| ACKNOWLEDGMENTS |
|---|
This work was supported by research grant GM19559 from the National Institute of General Medical Sciences. The Protein-DNA Core Facility at the University of Utah receives support from National Cancer Institute grant CA42014 to the Huntsman Cancer Institute.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Appl. Environ. Microbiol. | Infect. Immun. | Eukaryot. Cell |
|---|---|---|
| Mol. Cell. Biol. | J. Virol. | Microbiol. Mol. Biol. Rev. |
| ALL ASM JOURNALS |